Emmanuelle Leray

Pour plus de détails : voir sur MyHal

2025
1. Guillemin Francis, Romain Casey, Epstein Jonathan, Foucher Yohann, David Laplaud, et al.. Prognostic factors of disability progression in multiple sclerosis in real life: the OFSEP-high definition (OFSEP-HD) prospective cohort in France. BMJ Open, 2025, 15 (4), pp.e094688-e094688. ⟨10.1136/bmjopen-2024-094688⟩. ⟨hal-05033118⟩

2. Christine Lebrun-Frénay, Sandrine Kerbrat, Darin Okuda, Cassandre Landes-Chateau, Orhun H Kantarci, et al.. Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome. Multiple Sclerosis Journal, 2025, 31 (2), pp.184-196. ⟨10.1177/13524585241291471⟩. ⟨hal-04883813⟩

3. Mathilde Lefort, Olivier Dejardin, Eric Berger, Jean-Philippe Camdessanché, Jonathan Ciron, et al.. Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France. Multiple Sclerosis Journal, 2025, 31 (1), pp.69-80. ⟨10.1177/13524585241289276⟩. ⟨hal-04826502⟩

4. Mathilde Lefort, Olivier Dejardin, Eric Berger, Jean-Philippe Camdessanché, Jonathan Ciron, et al.. Association between education level and disability progression in patients with multiple sclerosis in France. Multiple Sclerosis Journal, 2025, 31 (1), pp.59-68. ⟨10.1177/13524585241289274⟩. ⟨hal-04814408⟩

5. Elisabeth Maillart, Fabien Rollot, Emmanuelle Leray, Lakhdar Benyahya, Bertrand Bourre, et al.. Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population. Multiple Sclerosis Journal, 2025, 31 (3), pp.324 – 337. ⟨10.1177/13524585251316474⟩. ⟨hal-05000197⟩

6. Marie Mainguy, Romain Casey, Sandra Vukusic, Christine Lebrun-Frenay, Eric Berger, et al.. Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation, 2025, 12 (2), pp.e200371. ⟨10.1212/NXI.0000000000200371⟩. ⟨hal-04947771⟩

2024
7. Nicolas Collongues, Françoise Durand-Dubief, Christine Lebrun-Frénay, Bertrand Audoin, Xavier Ayrignac, et al.. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society. Multiple Sclerosis Journal, 2024, Multiple Sclerosis Journal, 30 (7), pp.899-924. ⟨10.1177/13524585231223880⟩. ⟨hal-04479762⟩

8. M. Espagnacq, S. Guillaume, Emmanuelle Leray. Conséquences financières de la mise en invalidité des personnes atteintes de sclérose en plaques et points de vue des malades.. Questions d’économie de la santé, 2024, 289, pp.1-8. ⟨hal-04618296⟩

9. C. Lebrun-Frenay, C. Carra-Dallière, C. Louapre, C. Papeix, V. Pourcher, et al.. Recommandations de la Société francophone de la sclérose en plaques « Vaccinations et sclérose en plaques » : mise à jour 2024. Pratique Neurologique – FMC, 2024, 15 (2), pp.105-113. ⟨10.1016/j.praneu.2024.04.001⟩. ⟨hal-04578333⟩

10. Emmanuelle Leray, C. Regaert, E. Duguet, S. Guillaume, S. Pichetti, et al.. Impact of multiple sclerosis on employment and income: Insights from a random sample representative of private sector employees in France using longitudinal administrative data. Revue Neurologique, 2024, 180 (8), pp.754-765. ⟨10.1016/j.neurol.2024.02.389⟩. ⟨hal-04543869⟩

11. Romain Marignier, David Laplaud, Helene Zephir, Caroline Papeix, Emmanuelle Leray, et al.. Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study. Frontiers in Neurology, 2024, 14, pp.1303874. ⟨10.3389/fneur.2023.1303874⟩. ⟨hal-04432746⟩

12. Xavier Moisset, Emmanuelle Leray, Chouki Chenaf, Frederic Taithe, Sandra Vukusic, et al.. Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France. Neurology, 2024, 103 (5), pp.e209662. ⟨10.1212/wnl.0000000000209662⟩. ⟨hal-04698925⟩

13. Chloe Pierret, Aurelien Mulliez, Christine Le Bihan-Benjamin, Xavier Moisset, Philippe-Jean Bousquet, et al.. Cancer Risk Among Patients With Multiple Sclerosis. Neurology, 2024, 103 (9), pp.e209885. ⟨10.1212/WNL.0000000000209885⟩. ⟨hal-04735377⟩

14. C. Pierret, Marie Mainguy, Emmanuelle Leray. Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database. Revue Neurologique, 2024, 180 (5), pp.429-437. ⟨10.1016/j.neurol.2023.12.007⟩. ⟨hal-04487926⟩

15. Sandra Vukusic, Bertrand Bourre, Romain Casey, Kumaran Deiva, Anne-Marie Guennoc, et al.. The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics. Multiple Sclerosis Journal, 2024, Multiple Sclerosis Journal, 30 (2), pp.216-226. ⟨10.1177/13524585231223390⟩. ⟨hal-04432657⟩

2023
16. Floriane Calocer, Huah Shin Ng, Feng Zhu, Yinshan Zhao, Olivier Dejardin, et al.. Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis. Multiple Sclerosis Journal, 2023, 29 (3), pp.466-470. ⟨10.1177/13524585221129963⟩. ⟨hal-03882628⟩

17. Maude Espagnacq, Emmanuelle Leray, Camille Regaert, Alice Guilleux, Sylvain Pichetti, et al.. Difficultés de maintien en emploi à la suite d’une sclérose en plaques : perte de salaire et rôle des revenus de substitution dans les ressources. Questions d’économie de la santé, 2023, 274, pp.1-8. ⟨hal-04039661⟩

18. Christine Lebrun-Frénay, Darin Okuda, Aksel Siva, Cassandre Landes-Chateau, Christina Azevedo, et al.. The radiologically isolated syndrome: revised diagnostic criteria. Brain – A Journal of Neurology , 2023, 146 (8), pp.3431-3443. ⟨10.1093/brain/awad073⟩. ⟨hal-04020134⟩

19. Emmanuelle Leray. Sclerosi multipla: epidemiologia. EMC – Neurologia, 2023, 23 (4), pp.1-15. ⟨10.1016/S1634-7072(23)48431-0⟩. ⟨hal-04316052⟩

20. Emmanuelle Leray, Maude Espagnacq, Regaert Camille, Sylvain Pichetti, Guillaume Stéphanie, et al.. Impact de la SEP sur les trajectoires professionnelles [P29.29]. Revue Neurologique, 2023, 179 (supplément), pp.S158. ⟨10.1016/j.neurol.2023.01.679⟩. ⟨hal-04257519⟩

21. Marie Mainguy, Emmanuelle Le Page, Laure Michel, Emmanuelle Leray. Pregnancy-related healthcare utilization among women with multiple sclerosis. Frontiers in Neurology, 2023, 14, ⟨10.3389/fneur.2023.1129117⟩. ⟨hal-04021750⟩

22. J Medioni, D Scimeca, y Lopez Marquez, Emmanuelle Leray, M Dalichampt, et al.. Benefits of homeopathic complementary treatment in patients with breast cancer: A retrospective cohort study based on the French nationwide healthcare database. Clinical Breast Cancer, 2023, 23 (1), pp.60-70. ⟨10.1016/j.clbc.2022.10.001⟩. ⟨hal-03820830⟩

23. Fabien Rollot, Zoé Uhry, Emmanuelle Dantony, Mathieu Fauvernier, Laurent Remontet, et al.. Mortalité liée à la SEP et aux autres causes de décès chez les patients SEP [P29.32]. Revue Neurologique, 2023, 179 (supplément), pp.S158. ⟨10.1016/j.neurol.2023.01.682⟩. ⟨hal-04257509⟩

24. Fabien Rollot, Zoe Uhry, Emmanuelle Dantony, Sandra Vukusic, Marc Debouverie, et al.. Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks. Neurology, 2023, 101 (24), pp.e2483-e2496. ⟨10.1212/WNL.0000000000207925⟩. ⟨hal-04250392⟩

25. C. Sabathe, Romain Casey, S. Vukusic, Emmanuelle Leray, G. Mathey, et al.. Improving the decision to switch from first to second-line therapy in multiple sclerosis: a dynamic scoring system. Multiple Sclerosis Journal, 2023, 29 (2), pp.236-247. ⟨10.1177/13524585221139156⟩. ⟨hal-04221685⟩

26. Sandra Vukusic, Romain Marignier, Jonathan Ciron, Bertrand Bourre, Mikael Cohen, et al.. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. Multiple Sclerosis Journal, 2023, 29 (1), pp.37-51. ⟨10.1177/13524585221130934⟩. ⟨hal-04954569⟩

27. Sandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, Elisabeth Maillart, Laure Michel, et al.. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Multiple Sclerosis Journal, 2023, 29 (1), pp.11-36. ⟨10.1177/13524585221129472⟩. ⟨hal-03882738⟩

28. Sarah Wilson, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, et al.. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study. The Lancet Regional Health – Europe, 2023, 24, pp.100542. ⟨10.1016/j.lanepe.2022.100542⟩. ⟨hal-03875120⟩

29. Sharon A. Wilson, F. Calocer, F. Rollot, M. Fauvernier, L Remontet, et al.. Influence of socio-economic status on excess mortality of multiple sclerosis. Multiple Sclerosis Journal, 2023, 28 (3_SUPPL), pp.456-457. ⟨hal-03925229⟩

2022
30. Alix Callens, Soline Leblanc, Emmanuelle Le Page, Gilles Edan, Aurore Jourdain, et al.. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Multiple Sclerosis and Related Disorders, 2022, 66, pp.104066. ⟨10.1016/j.msard.2022.104066⟩. ⟨hal-03753568⟩

31. Adeline Degremont, Sandrine Kerbrat, Frédéric Balusson, Annie Pierre Jonville-Bera, Virginie Ringa, et al.. Prescribing Trends for Valproate Among Pregnant Women: A Cross-sectional Study in 2013 and 2016 Using the French Health Insurance Database. Neurology, 2022, 98 (21), pp.e2163-e2173. ⟨10.1212/WNL.0000000000200260⟩. ⟨hal-03637138⟩

32. Soline Leblanc, Mathilde Lefort, Emmanuelle Le Page, Laure Michel, Emmanuelle Leray. Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France. Expert Review of Neurotherapeutics, 2022, 22 (5), pp.411-418. ⟨10.1080/14737175.2022.2061950⟩. ⟨hal-03629848⟩

33. Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray. Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments. European Journal of Neurology, 2022, 29 (9), pp.2761-2771. ⟨10.1111/ene.15422⟩. ⟨hal-03690316⟩

34. Mathilde Lefort, O. Dejardin, F. Calocer, G. Defer, Emmanuelle Leray. Impact of education level on multiple sclerosis disability progression in France. Multiple Sclerosis Journal, 2022, 28 (3_SUPPL), pp.113-114. ⟨hal-03925167⟩

35. Mathilde Lefort, S. Sharmin, J. Andersen, S. Vukusic, R. Casey, et al.. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Medical Research Methodology, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩. ⟨hal-03690493⟩

36. Mathilde Lefort, G. Le Corre, E. Le Page, C. Rizzato, D. Le Port, et al.. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. Revue Neurologique, 2022, 178 (6), pp.569-579. ⟨10.1016/j.neurol.2021.11.014⟩. ⟨hal-03588900⟩

37. Soizic Leguy, Mathilde Lefort, Lucile Lescot, Audrey Michaud, Sandra Vukusic, et al.. COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. Journal of Neurology, 2022, 269 (269), pp.5571-5581. ⟨10.1007/s00415-022-11215-7⟩. ⟨hal-03704177⟩

38. Lucile Lescot, Mathilde Lefort, Soizic Leguy, Emmanuelle Le Page, Sandra Vukusic, et al.. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 68, pp.104122. ⟨10.1016/j.msard.2022.104122⟩. ⟨hal-03776859⟩

39. M. Mainguy, E. Le Page, Laure Michel, Emmanuelle Leray. Use of pregnancy-related healthcare in women with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28 (3_SUPPL), pp.461-462. ⟨hal-03922624⟩

40. Marie Mainguy, Hélène Tillaut, Adeline Degremont, Emmanuelle Le Page, Christelle Mainguy, et al.. Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis. Neurology, 2022, 99 (17), pp.10.1212/WNL.0000000000201027. ⟨10.1212/WNL.0000000000201027⟩. ⟨hal-03751891⟩

41. Caroline Papeix, Giovanni Castelnovo, Emmanuelle Leray, Marc Coustans, Pierre Levy, et al.. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Neurology and Therapy, 2022, ⟨10.1007/s40120-022-00334-y⟩. ⟨hal-03608016⟩

42. Fabien Rollot, Justine Couturier, Romain Casey, Sandrine Wiertlewski, Marc Debouverie, et al.. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. Neurotherapeutics, 2022, 19 (2), pp.476-490. ⟨10.1007/s13311-022-01202-1⟩. ⟨hal-03594074⟩

43. Fabien Rollot, Couturier Justine, Romain Casey, Emmanuelle Leray, Sandra Vukusic, et al.. Comparaison des anti-CD20 et du natalizumab chez des patients avec une SEP très active. Revue Neurologique, 2022, 178 (Suppl.), pp.S111. ⟨10.1016/j.neurol.2022.02.381⟩. ⟨hal-03820845⟩

44. I. Roos, C. B. Malpas, E. Leray, K. Buzzard, O. Skibina, et al.. Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, pp.6-7. ⟨10.1136/bmjno-2021-anzan.8⟩. ⟨hal-04056223⟩

45. Izanne Roos, Charles Malpas, Emmanuelle Leray, Romain Casey, Dana Horakova, et al.. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2022, 99 (17), pp.e1926-e1944. ⟨10.1212/WNL.0000000000201029⟩. ⟨hal-03776286⟩

46. I. Roos, Emmanuelle Leray, K. Buzzard, O. Skibina, J. Lechner-Scott, et al.. High and low efficacy therapy in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, pp.6-6. ⟨10.1212/WNL.96.15_supplement.266⟩. ⟨hal-04056219⟩

47. Jonathan Roux, Elaine Kingwell, Feng Zhu, Helen Tremlett, Emmanuelle Leray. Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada. Multiple Sclerosis Journal, 2022, 28 (2), pp.309-322. ⟨10.1177/13524585211016726⟩. ⟨hal-03246670⟩

48. Hélène Tillaut, Adeline Degrémont, Sandrine Kerbrat, Jonathan Roux, Emmanuelle Le Page, et al.. Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28 (5), pp.778-789. ⟨10.1177/13524585211035376⟩. ⟨hal-03819581⟩

49. Sandra Vukusic, Jonathan Ciron, Clarisse Carra-Dalliere, Elisabeth Maillart, Laure Michel, et al.. Pregnancy in women with Neuromyelitis Optica Spectrum Disorders: Recommendations from the French Multiple Sclerosis Society (P13-4.006). Neurology, 2022, 98 (18(supplement)), pp.1741. ⟨10.1212/wnl.98.18_supplement.1741⟩. ⟨hal-03922758⟩

2021
50. Johanna Andersen, Sifat Sharmin, Mathilde Lefort, Nils Koch-Henriksen, Finn Sellebjerg, et al.. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩. ⟨hal-03268539⟩

51. Mohammed Bennani, Jacques Medioni, Yecenia Lopez Marquez, Daniel Scimeca, Emmanuelle Leray, et al.. Benefits of homeopathic complementary treatment in breast cancer patients. A retrospective cohort.. European Journal of Integrative Medicine, 2021, 48, pp.101915. ⟨10.1016/j.eujim.2021.101915⟩. ⟨hal-03820857⟩

52. Olivier Grimaud, Sahar Bayat, Anne Renault, Eric Maury, Julien Pottecher, et al.. TRANSCOV cohort protocol: an epidemiological study assessing the impact of critically ill COVID-19 patients long distance transfers between intensive care units. BMJ Open, 2021, 11 (10), pp.e054774. ⟨10.1136/bmjopen-2021-054774⟩. ⟨hal-03405771⟩

53. Soline Leblanc, Jonathan Roux, Hélène Tillaut, Emmanuelle Le Page, Emmanuelle Leray. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Revue Neurologique, 2021, 177 (10), pp.1250-1261. ⟨10.1016/j.neurol.2021.04.006⟩. ⟨hal-03312766⟩

54. Jacques Medioni, Daniel Scimeca, Ycenia Lopez Marquez, Emmanuelle Leray, Marie Dalichampt, et al.. Apports de la prise en charge homéopathique en soins de support dans le cancer du sein : Impact sur la consommation des traitements palliant les effets indésirables liés à la prise en charge du cancer du sein – Étude d’après les données du Système National des Données de Santé (SNDS). Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2021, 69 (suppl. 2), pp.S88-S89. ⟨10.1016/j.respe.2021.05.011⟩. ⟨hal-03820863⟩

55. Fabien Rollot, Mathieu Fauvernier, Zoe Uhry, Sandra Vukusic, Nadine Bossard, et al.. Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. Neurology, 2021, 97 (4), pp.e403-e413. ⟨10.1212/WNL.0000000000012224⟩. ⟨hal-03246632⟩

56. Fabien Rollot, Romain Casey, Emmanuelle Leray, Marc Debouverie, Gilles Edan, et al.. Cumulative effects of therapies on disability in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27 (11), pp.1760-1770. ⟨10.1177/1352458520980366⟩. ⟨hal-03128421⟩

57. Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, et al.. Determinants of Therapeutic Lag in Multiple Sclerosis. Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩. ⟨hal-03223056⟩

58. Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, et al.. Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97 (9), pp.e869-e880. ⟨10.1212/WNL.0000000000012354⟩. ⟨hal-03282036⟩

59. Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, David-Axel Laplaud, et al.. Emulation d’essai clinique randomisé chez des patients atteints d’une sclérose en plaques pour estimer le bénéfice d’un changement de traitement précoce vers un traitement de seconde ligne : approche par scores de propensions dépendant du temps. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2021, 69, pp.S85. ⟨10.1016/j.respe.2021.05.007⟩. ⟨hal-03820873⟩

60. Marc-Antoine Sanchez, Albert Vuagnat, Olivier Grimaud, Emmanuelle Leray, Jean-Marc Philippe, et al.. Impact of ICU transfers on the mortality rate of patients with COVID-19: insights from comprehensive national database in France. Annals of Intensive Care, 2021, 11 (1), ⟨10.1186/s13613-021-00933-2⟩. ⟨hal-03411986⟩

61. Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, et al.. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩. ⟨hal-03367246⟩

62. Alice J. Sommer, Emmanuelle Leray, Young Lee, Marie-Abele C. Bind. Assessing environmental epidemiology questions in practice with a causal inference pipeline: An investigation of the air pollution-multiple sclerosis relapses relationship. Statistics in Medicine, 2021, 40 (6), pp.1321-1335. ⟨10.1002/sim.8843⟩. ⟨hal-03101469⟩

2020
63. Kevin Ahrweiller, Chloé Rousseau, Emmanuelle Le Page, Emma Bajeux, Emmanuelle Leray, et al.. Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2020, 26 (8), pp.924-935. ⟨10.1177/1352458519848090⟩. ⟨hal-02150346⟩

64. Astrid Barataud-Reilhac, Sandrine Kerbrat, Jonathan Roux, Alice Guilleux, Elisabeth Polard, et al.. Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis. Neurology: Clinical Practice, 2020, 10 (4), pp.287-297. ⟨10.1212/CPJ.0000000000000717⟩. ⟨hal-02955236⟩

65. Laura Couloume, Laetitia Barbin, Emmanuelle Leray, Sandrine Wiertlewski, Emmanuelle Le Page, et al.. High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice. Multiple Sclerosis Journal, 2020, 26 (14), pp.1898-1906. ⟨10.1177/1352458519894713⟩. ⟨hal-02436685⟩

66. C. Donzé, C. Papeix, C. Lebrun-Frenay, N. Collongues, M. de Seze, et al.. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, 2020, 176 (10), pp.804-822. ⟨10.1016/j.neurol.2020.02.011⟩. ⟨hal-03339824⟩

67. Alice Guilleux, Jonathan Roux, David Travers, Emmanuelle Leray. Prevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with rheumatoid arthritis in France. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2020, 6 (3), pp.2055217320941540. ⟨10.1177/2055217320941540⟩. ⟨hal-02960099⟩

68. Julie Havas, Emmanuelle Leray, Fabien Rollot, Romain Casey, Laure Michel, et al.. Predictive medicine in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 40, pp.101928. ⟨10.1016/j.msard.2020.101928⟩. ⟨hal-02470973⟩

69. Viviane Kovess-Masféty, Frédéric Balusson, Emmanuelle Leray, Mathilde Husky, Lucie-Marie Scailteux. Prescription patterns of first- and second-generation antipsychotic drugs in the French population. Fundamental & Clinical Pharmacology, 2020, 34 (5), pp.603-611. ⟨10.1111/fcp.12553⟩. ⟨hal-02534802⟩

70. Mathilde Lefort, Yohann Foucher, Rémi Lenain, Sandra Vukusic, Gilles Edan, et al.. Long‐term effect of first‐line injectable multiple sclerosis treatments: input of a time‐dependent propensity score. Pharmacoepidemiology and Drug Safety, 2020, 29 (12), pp.1680-1688. ⟨10.1002/pds.5154⟩. ⟨hal-02979802⟩

71. Emmanuelle Leray, A. Bastien, K. Rerat, A. Cognee-Chauvin, E. Raponi, et al.. Clinical course and therapeutic management of spms in france: a retrospective real world multicentric observational study (odyssep study). Multiple Sclerosis Journal, 2020, 26 (3_SUPPL), pp.524-525. ⟨hal-03105858⟩

72. Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, et al.. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain – A Journal of Neurology , 2020, 143 (9), pp.2742-2756. ⟨10.1093/brain/awaa231⟩. ⟨hal-02955197⟩

73. Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, Dana Horakova, et al.. Determinants of Therapeutic Lag in Multiple Sclerosis. Neurology, 2020, 94 (15), ⟨10.1212/WNL.94.15_supplement.2059⟩. ⟨hal-02929410⟩

74. Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, Dana Horakova, et al.. Identification of Therapeutic Lag in Multiple Sclerosis. Neurology, 2020, 94 (15). ⟨hal-02929403⟩

75. I. Roos, Emmanuelle Leray, Romain Casey, D. Horakova, E. Kubala Havrdova, et al.. High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag. Multiple Sclerosis Journal, 2020, 26 (3_SUPPL), pp.534-535. ⟨hal-03127244⟩

76. C Walton, Rachel King, Lindsay Rechtman, Wendy Kaye, Emmanuelle Leray, et al.. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 2020, 26 (14), pp.1816-1821. ⟨10.1177/1352458520970841⟩. ⟨hal-03038709⟩

2019
77. Romain Casey, I. El-Bahi, F. Rollot, Francis Guillemin, D. -A. Laplaud, et al.. Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients’ characteristics. Multiple Sclerosis Journal, 2019, 25 (2_suppl), pp.196-196. ⟨10.1177/1352458519868078⟩. ⟨hal-02363488⟩

78. Elaine Kingwell, Emmanuelle Leray, Feng Zhu, John Petkau, Gilles Edan, et al.. Multiple sclerosis: effect of beta interferon treatment on survival. Brain – A Journal of Neurology , 2019, 142 (5), pp.1324-1333. ⟨10.1093/brain/awz055⟩. ⟨hal-02088095⟩

79. David-Axel Laplaud, Romain Casey, Laetitia Barbin, Marc Debouverie, Jerome de Sèze, et al.. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩. ⟨inserm-02289153⟩

80. C. Lebrun, S. Vukusic, V. Abadie, C. Achour, F. Ader, et al.. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, 2019, 175 (6), pp.341-357. ⟨10.1016/j.neurol.2019.04.001⟩. ⟨hal-02546158⟩

81. Mathilde Lefort, Yohann Foucher, Rémi Lenain, Sandra Vukusic, Gilles Edan, et al.. Long-term effect of interferon and Glatiramer acetate in real-world settings use on multiple sclerosis disability progression: Input of time-dependent propensity score. Pharmacoepidemiology and Drug Safety, 2019, 28, pp.217-218. ⟨hal-02302564⟩

82. Mathilde Lefort, Vukusic Sandra, Romain Casey, Gilles Edan, Emmanuelle Leray. Effet de l’initiation précoce d’un traitement de fond sur la progression du handicap en sclérose en plaques rémittente : une étude observationnelle des données de l’OFSEP. Revue Neurologique, 2019, 175, pp.S87. ⟨10.1016/j.neurol.2019.01.243⟩. ⟨hal-02921500⟩

83. Emmanuelle Leray, F. Mamadou, A. Guilleux, Jonathan Roux, Olivier Grimaud. Geographical variations in access to expert centers for multiple sclerosis in France. European Journal of Public Health, 2019, 29 (Supplement_4), pp.80-80. ⟨10.1093/eurpub/ckz185.205⟩. ⟨hal-02470788⟩

84. Emmanuelle Leray, M. Peron, Christophe Fermanian, E. Maillart, K. Deiva. Prevalence of paediatric-onset multiple sclerosis in France, disease management and use of disease-modifying therapies in this specific population. Multiple Sclerosis Journal, 2019, 25, pp.148-148. ⟨hal-02363489⟩

85. Fabien Rollot, Romain Casey, Emmanuelle Leray, Marc Debouverie, Gilles Edan, et al.. Évaluation des effets cumulés de traitement de fonds sur le risque de handicap chez les patients récurrents-rémittents. Revue Neurologique, 2019, 175 (Supplément 1), pp.S77. ⟨10.1016/j.neurol.2019.01.219⟩. ⟨hal-02921630⟩

86. F. Rollot, M. Fauvernier, Z. Uhry, S. Vukusic, N. Bossard, et al.. Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on French OFSEP data (‘Observatoire Francais de la Sclerose en Plaques’). Multiple Sclerosis Journal, 2019, 25, pp.103-104. ⟨hal-02363491⟩

87. Jonathan Roux, Olivier Grimaud, Emmanuelle Leray. Use of state sequence analysis for care pathway analysis: The example of multiple sclerosis. Statistical Methods in Medical Research, 2019, 28 (6), pp.1651-1663. ⟨10.1177/0962280218772068⟩. ⟨hal-01798652⟩

88. Jonathan Roux, Alice Guilleux, Mathilde Lefort, Emmanuelle Leray. Descriptif des caractéristiques des personnes ayant une sclérose en plaques en France et de leur recours aux soins à partir du Système National des Données de Santé en 2010-2015. Revue Neurologique, 2019, 175 (N° S1), pp.S86-S87. ⟨10.1016/j.neurol.2019.01.241⟩. ⟨hal-02921515⟩

89. Jonathan Roux, Alice Guilleux, Mathilde Lefort, Emmanuelle Leray. Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2019, 5 (4), pp.2055217319896090. ⟨10.1177/2055217319896090⟩. ⟨hal-02444012⟩

2018
90. Emma Bajeux, David Klemanski, Mathilde Husky, Emmanuelle Leray, Christine Chan Chee, et al.. Factors Associated with Parent–Child Discrepancies in Reports of Mental Health Disorders in Young Children. Child Psychiatry and Human Development, 2018, 49 (6), pp.1003-1010. ⟨10.1007/s10578-018-0815-7⟩. ⟨hal-02436693⟩

91. Romain Casey, Francis Guillemin, D. A. Laplaud, Emmanuelle Leray, J. Epstein, et al.. The OFSEP high definition cohort to prognosticate the evolution of multiple sclerosis at clinical key steps of the disease. Multiple Sclerosis Journal, 2018, 24, pp.772-772. ⟨10.26226/morressier.5b719e445aff74008ae4cb10⟩. ⟨hal-01939727⟩

92. A. Guilleux, Jonathan Roux, Emmanuelle Leray. Comorbidités mentales et sclérose en plaques : étude française à partir des données de l’Assurance maladie. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2018, 66 (suppl 1), pp.S44. ⟨10.1016/j.respe.2018.01.098⟩. ⟨hal-01740308⟩

93. A. Guilleux, Jonathan Roux, Emmanuelle Leray. Care-seeking and disease modifying therapies use among multiple sclerosis patients with and without mental disorders – a population-based study. Multiple Sclerosis Journal, 2018, 24, pp.377-378. ⟨hal-01935070⟩

94. Maxime Jeanjean, Marie-Abele Bind, Jonathan Roux, Jean-Claude Ongagna, Jérôme de Sèze, et al.. Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. Environmental Research, 2018, 163, pp.43-52. ⟨10.1016/j.envres.2018.01.040⟩. ⟨hal-01740486⟩

95. Mathilde Lefort, Gilles Edan, Emmanuelle Leray. Propensity score methods The study of the effect of beta-interferon and glatiramer acetate on multiple sclerosis disability. Pharmacoepidemiology and Drug Safety, 2018, 27, pp.191-192. ⟨hal-01879623⟩

96. Emmanuelle Leray, A. Reilhac, S. Kerbrat, Jonathan Roux, E. Polard. Incidence of pregnancy in women with multiple sclerosis treated with teriflunomide in France. Multiple Sclerosis Journal, 2018, 24, pp.715-715. ⟨hal-01939729⟩

97. Emmanuelle Leray, Fabien Rollot, Romain Casey, Jonathan Roux, Jérôme de Seze, et al.. Quelle utilisation des traitements de fond chez des patients ayant une SEP rémittente en France sur la période 1990–2017 ? Éléments de réponse à partir des données de l’Ofsep. Revue Neurologique, 2018, 174, pp.S101. ⟨10.1016/j.neurol.2018.01.228⟩. ⟨hal-02921615⟩

98. Emmanuelle Leray, Jonathan Roux, F. Rollot, Romain Casey, J. de Seze, et al.. Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990–2017 ? Étude des données de l’Observatoire français de la SEP. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2018, 66, pp.S227. ⟨10.1016/j.respe.2018.04.033⟩. ⟨hal-02921604⟩

99. F. Rollot, Romain Casey, Marc Debouverie, Gilles Edan, S. Wiertlewski, et al.. Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, pp.344-345. ⟨hal-01935071⟩

100. Jonathan Roux, A. Guilleux, Olivier Grimaud, Emmanuelle Leray. Care-seeking of patients with multiple sclerosis over 2010-2015 in France – a nationwide study using health administrative data. Multiple Sclerosis Journal, 2018, 24, pp.550-551. ⟨hal-01935074⟩

101. Jonathan Roux, Olivier Grimaud, Emmanuelle Leray. Étude des parcours de soins des patients ayant une sclérose en plaques en France sur la période 2007–2013 : une analyse des bases médico-administratives utilisant la méthode « Multichannel Sequence Analysis ». Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2018, 66 (suppl 1), pp.S25. ⟨10.1016/j.respe.2018.01.053⟩. ⟨hal-01740314⟩

102. Jonathan Roux, Olivier Grimaud, Emmanuelle Leray. Multichannel sequence analysis: An innovative method to study patterns of care pathways. Application to multiple sclerosis based on French Health Insurance data. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2018, 66, pp.S430-S431. ⟨10.1016/j.respe.2018.05.534⟩. ⟨hal-02921552⟩

103. Jonathan Roux, Alice Guilleux, Emmanuelle Leray. Impact of new oral disease-modifying therapies on the prescription of injectable and off-label drugs in multiple sclerosis in France over 2011-2015 using national administrative databases. Pharmacoepidemiology and Drug Safety, 2018, 27, pp.319-320. ⟨hal-01879625⟩

104. V. Schlegel, Emmanuelle Leray. From medical prescription to patient compliance. A qualitative insight into the neurologist-patient relationship in multiple sclerosis. International Journal of MS Care, 2018, 20 (6), pp.279-286. ⟨10.7224/1537-2073.2017-043⟩. ⟨hal-02043814⟩

2017
105. K. Ahrweiller, Chloé Rousseau, Emmanuelle Leray, Emmanuelle Le Page, Emma Bajeux, et al.. Relapses in patients with secondary progressive MS a matter of disease duration or age?. Multiple Sclerosis Journal, 2017, 23, pp.60-60. ⟨hal-01715985⟩

106. A. Gallini, F. Moisan, G. Maura, L. Carcaillon-Bentata, Emmanuelle Leray, et al.. Identification des maladies neurodégénératives dans les bases de données médicoadministratives en France : revue systématique de la littérature. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2017, 65 (4), pp.S183-S197. ⟨10.1016/j.respe.2017.01.115⟩. ⟨hal-01519864⟩

107. A. Guilleux, Jonathan Roux, Emmanuelle Leray. Mood disorders and multiple sclerosis: a study based upon the French national health insurance databases. Multiple Sclerosis Journal, 2017, 23, pp.755-755. ⟨10.26226/morressier.59a3e8b5d462b8028d8946e3⟩. ⟨hal-01713271⟩

108. M. Jeanjean, M. -A. Bind, Jonathan Roux, J. -C. Ongagna, J. de Seze, et al.. Short-term exposure to ambient air pollution and occurrence of multiple sclerosis relapses. Multiple Sclerosis Journal, 2017, 23, pp.209-210. ⟨hal-01715987⟩

109. Shoshannah Kalson-Ray, Gilles Edan, Emmanuelle Leray. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. Multiple Sclerosis Journal, 2017, 23 (6), pp.864-871. ⟨10.1177/1352458517699873⟩. ⟨hal-01518889⟩

110. Mathilde Lefort, M. Goetz, Gilles Edan, Emmanuelle Leray. Long-term effect of interferon-beta use in real-world settings on disability progression a series of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France. Multiple Sclerosis Journal, 2017, 23, pp.633-634. ⟨10.26226/morressier.59a3edacd462b8028d8954cb⟩. ⟨hal-01715984⟩

111. Emmanuelle Leray, F. Rollot, Romain Casey, J. de Seze, D. A. Laplaud, et al.. Disease-modifying therapies use in primary progressive multiple sclerosis patients in France data from the OFSEP cohort over the 1996-2017 period. Multiple Sclerosis Journal, 2017, 23, pp.659-660. ⟨10.26226/morressier.59a3edacd462b8028d8957a8⟩. ⟨hal-01716028⟩

112. Emmanuelle Leray, F. Rollot, Romain Casey, J. de Seze, D. A. Laplaud, et al.. Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017. Multiple Sclerosis Journal, 2017, 23, pp.709-709. ⟨10.26226/morressier.59a3e8b4d462b8028d894343⟩. ⟨hal-01716027⟩

113. Jonathan Roux, Olivier Grimaud, Emmanuelle Leray. Care consumption of multiple sclerosis patients in France an analysis of health insurance administrative databases using multichannel sequence analysis from 2007 to 2013. Multiple Sclerosis Journal, 2017, 23, pp.717-717. ⟨10.26226/morressier.59a3e8b4d462b8028d8942e9⟩. ⟨hal-01715986⟩

114. Jonathan Roux, Denis Bard, Estelle Le Pabic, Claire Ségala, Jacques Reis, et al.. Air pollution by particulate matter PM10 may trigger multiple sclerosis relapses. Environmental Research, 2017, 156, pp.404-410. ⟨10.1016/j.envres.2017.03.049⟩. ⟨hal-01519866⟩

115. Jonathan Roux, A. Guilleux, Emmanuelle Leray. Adherence to oral versus injectable disease-modifying therapies for multiple sclerosis using French national health insurance databases. Multiple Sclerosis Journal, 2017, 23, pp.899-900. ⟨10.26226/morressier.59a3e8b6d462b8028d8954f3⟩. ⟨hal-01684631⟩

2016
116. L. Calderón-Garcidueñas, Emmanuelle Leray, P. Heydarpour, R. Torres-Jardón, J Reis. Air pollution, a rising environmental risk factor for cognition, neuroinflammation and neurodegeneration: The clinical impact on children and beyond. Revue Neurologique, 2016, 172 (1), pp.69-80. ⟨10.1016/j.neurol.2015.10.008⟩. ⟨hal-01255833⟩

117. Viviane Kovess-Masféty, Emmanuelle Leray, Laure Denis, Mathilde Husky, Isabelle Pitrou, et al.. Mental health of college students and their non-college-attending peers: results from a large French cross-sectional survey. BMC Psychology, 2016, 4, pp.20. ⟨10.1186/s40359-016-0124-5⟩. ⟨hal-02436738⟩

118. Emmanuelle Leray, J. Roux, Olivier Grimaud. Consommations de soins des patients ayant une sclérose en plaques traités par fingolimod à partir d’un échantillon au 1/97e des données de l’assurance maladie en France. Revue Neurologique, 2016, 172, pp.A94 – A95. ⟨10.1016/j.neurol.2016.01.228⟩. ⟨hal-01740321⟩

119. Emmanuelle Leray, Estelle Le Pabic, J. Roux, Jean-Claude Ongagna, Denis Bard, et al.. La survenue de poussées de sclérose en plaques influencée par le niveau de particules fines PM10 dans l’air. Revue Neurologique, 2016, 172, ⟨10.1016/j.neurol.2016.01.050⟩. ⟨hal-01740319⟩

120. Emmanuelle Leray, Thibault Moreau, Agnès Fromont, Gilles Edan. Epidemiology of multiple sclerosis. Revue Neurologique, 2016, 172 (1), pp.3-13. ⟨10.1016/j.neurol.2015.10.006⟩. ⟨hal-01255824⟩

121. Diane Pivot, Marc Debouverie, Michel Grzebyk, David Brassat, Michel Clanet, et al.. Geographical Heterogeneity of Multiple Sclerosis Prevalence in France. PLoS ONE, 2016, 11 (12), pp.e0167556 (eCollection 2016). ⟨10.1371/journal.pone.0167556⟩. ⟨inserm-01576154⟩

122. J. Roux, Nolwenn Le Meur, Olivier Grimaud, Emmanuelle Leray. Consommations de soins des patients atteints de sclérose en plaques en France de 2007 à 2013 à partir des bases de données médico-administratives. Revue Neurologique, 2016, 172, ⟨10.1016/j.neurol.2016.01.212⟩. ⟨hal-01740325⟩

123. J. Roux, Olivier Grimaud, Emmanuelle Leray. Peut-on mesurer le niveau de handicap moteur lié à la sclérose en plaques à partir des bases de l’Assurance maladie ?. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2016, 64 (suppl 4), pp.S199. ⟨10.1016/j.respe.2016.06.076⟩. ⟨hal-01740317⟩

124. J. Roux, Nolwenn Le Meur, Olivier Grimaud, Emmanuelle Leray. Utilisation des bases médico-administratives pour l’étude des parcours de soins des patients atteints de sclérose en plaques en France de 2007 à 2013. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2016, 64, pp.S18 – S19. ⟨10.1016/j.respe.2016.01.061⟩. ⟨hal-01740327⟩

2015
125. Nathalie Caucheteux, Adil Maarouf, Margaux Genevray, Emmanuelle Leray, Romain Deschamps, et al.. Criteria improving multiple sclerosis diagnosis at the first MRI. Journal of Neurology, 2015, 262 (4), pp.979 – 987. ⟨10.1007/s00415-015-7668-9⟩. ⟨hal-01378308⟩

126. Nathalie Durivage, Katherine Keyes, Emmanuelle Leray, Ondine Pez, Adina Bitfoi, et al.. Parental Use of Corporal Punishment in Europe: Intersection between Public Health and Policy. PLoS ONE, 2015, 10 (2), pp.e0118059. ⟨10.1371/journal.pone.0118059⟩. ⟨hal-02436918⟩

127. Anne Kerbrat, S Hamonic, Emmanuelle Leray, I Tron, Gilles Edan, et al.. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.. European Journal of Neurology, 2015, 22 (3), pp.507-e35. ⟨10.1111/ene.12600⟩. ⟨inserm-01103117⟩

128. Viviane Kovess, Sabine Choppin, Fei Gao, Mathilde Pivette, Mathilde Husky, et al.. Psychotropic medication use in French children and adolescents. Journal of Child and Adolescent Psychopharmacology, 2015, 25 (2), pp.168–175. ⟨10.1089/cap.2014.0058⟩. ⟨hal-01147097⟩

129. Nolwenn Le Meur, Sahar Bayat, Florence Clesse, Emmanuelle Leray, Florence Bodeau-Livinec, et al.. Bereavement-related depression: Did the changes induced by DSM-V make a difference? Results from a large population-based survey of French residents. Journal of Affective Disorders, 2015, 182 (1), pp.82-90. ⟨10.1016/j.jad.2015.04.039⟩. ⟨hal-02460653⟩

130. Emmanuelle Le Page, Véronique Deburghgraeve, Marie-Antoinette Lester, Isabelle Cardiet, Emmanuelle Leray, et al.. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.. Journal of Neurology, 2015, 262 (4), pp.1024-1034. ⟨10.1007/s00415-015-7653-3⟩. ⟨hal-01132657⟩

131. Emmanuelle Leray, Sandra Vukusic, Marc Debouverie, Michel Clanet, Bruno Brochet, et al.. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS ONE, 2015, 10 (7), pp.1-12. ⟨10.1371/journal.pone.0132033⟩. ⟨hal-01201656⟩

132. Emmanuelle Leray, E. Le Pabic, Christophe Fermanian, J. C. Ongagna, Denis Bard, et al.. Does air pollution influence risk of relapse in multiple sclerosis?. Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 11, pp.742–743. ⟨hal-01259394⟩

133. Julie A. Péron, Pascale Piolino, Sandrine Le Moal-Boursiquot, Isabelle Biseul, Emmanuelle Leray, et al.. Preservation of Person-Specific Semantic Knowledge in Semantic Dementia: Does Direct Personal Experience Have a Specific Role?. Frontiers in Human Neuroscience, 2015, 9, pp.625. ⟨10.3389/fnhum.2015.00625⟩. ⟨hal-01239805⟩

134. Jacqueline Yaouanq, Isabelle Tron, Anne Kerbrat, Emmanuelle Leray, S Hamonic, et al.. Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001.. Acta Neurologica Scandinavica Supplementum, 2015, 131 (5), pp.321-328. ⟨10.1111/ane.12332⟩. ⟨inserm-01103109⟩

2014
135. Olivier Grimaud, Emmanuelle Leray, Benoît Lalloué, Radouane Aghzaf, Jérôme Durier, et al.. Mortality following stroke during and after acute care according to neighbourhood deprivation: a disease registry study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85 (12), pp.1313-1318. ⟨10.1136/jnnp-2013-307283⟩. ⟨hal-02436963⟩

136. Emmanuelle Leray, Denis Bard, J.-C. Ongagna, J. de Seze. Pollution atmosphérique et déclenchement de poussées de sclérose en plaques [Communication]. Revue Neurologique, 2014, 170 (Supplement 1), pp.A235-A236. ⟨10.1016/j.neurol.2014.01.537⟩. ⟨hal-04026596⟩

137. Isabelle Ract, Jean-Christophe Ferré, Thomas Ronzière, Emmanuelle Leray, Béatrice Carsin-Nicol, et al.. Improving detection of ischemic lesions at 3Tesla with optimized diffusion-weighted magnetic resonance imaging. Journal de Neuroradiologie / Journal of Neuroradiology, 2014, 41 (1), pp.45-51. ⟨10.1016/j.neurad.2013.04.003⟩. ⟨inserm-00845255⟩

2013
138. O. Barbier, B. Galaud, S. Descamps, P. Boisrenoult, Emmanuelle Leray, et al.. Relevancy and reproducibility of magnetic resonance imaging (MRI) interpretation in multiple-ligament injuries and dislocations of the knee. Orthopaedics & Traumatology: Surgery & Research, 2013, 99 (3), pp.305-311. ⟨10.1016/j.otsr.2012.11.016⟩. ⟨hal-02436991⟩

139. O. Barbier, B. Galaud, S. Descamps, P. Boisrenoult, Emmanuelle Leray, et al.. Pertinence et reproductibilité de l’interprétation de l’IRM dans les luxations et les lésions ligamentaires bicroisées du genou. Revue de Chirurgie Orthopédique et Traumatologique, 2013, 99 (3), pp.269-274. ⟨10.1016/j.rcot.2012.11.017⟩. ⟨hal-02437002⟩

140. Olivier Grimaud, Emmanuelle Leray, B. Lalloué, J. Durier, M. Giroud, et al.. Inégalités sociales vis-à-vis de la létalité consécutive à un accident vasculaire cérébral, Dijon, France. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2013, 61 (Supplement 4), pp.S315. ⟨10.1016/j.respe.2013.07.375⟩. ⟨hal-04021813⟩

141. Olivier Grimaud, Emmanuelle Leray, A. Alperovitch, C. Dufouil, P. Chauvin. Effets antagonistes de l’éducation et du revenu sur le risque d’accident vasculaire cérébral ischémique au sein d’une cohorte de personnes âgées. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2013, 61 (Supplement 2), pp.S112. ⟨10.1016/j.respe.2013.03.019⟩. ⟨hal-04021795⟩

142. Emmanuelle Leray, M. Coustans, Emmanuelle Le Page, J. Yaouanq, Joel Oger, et al.. ‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.. Multiple Sclerosis Journal, 2013, 19 (4), pp.458-65. ⟨10.1177/1352458512456613⟩. ⟨hal-00878705⟩

143. Emmanuelle Leray, L. Denis, Viviane Kovess-Masfety. Des différences d’état de santé mentale entre actifs, scolarisés et demandeurs d’emploi chez les 18–24ans, France. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2013, 61 (Supplement 4), pp.S270-S271. ⟨10.1016/j.respe.2013.07.214⟩. ⟨hal-04021827⟩

144. Serge A. Massengo, M. Cisse, C. Guiziou, Emmanuelle Leray, Yusuf A. Rajabally, et al.. Knowledge of TIA among general practitioners and emergency department physicians. A questionnaire survey in a French semi-rural area. Clinical Neurology and Neurosurgery, 2013, 115 (8), pp.1457 – 1463. ⟨10.1016/j.clineuro.2013.01.026⟩. ⟨hal-01576986⟩

2012
145. Emmanuelle Leray, G. Edan. Survimus, une étude multicentrique de la mortalité dans la sclérose en plaques, France. Epidemiology and Public Health = Revue d’Epidémiologie et de Santé Publique, 2012, 60 (Supplement 2), pp.S59-S60. ⟨10.1016/j.respe.2012.06.056⟩. ⟨hal-04021788⟩

2011
146. Sophie Drapier, Anne-Sophie Gillioz, Emmanuelle Leray, Julie Péron, Tiphaine Rouaud, et al.. Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications.. Parkinsonism & Related Disorders, 2011, 18 (1), pp.40-4. ⟨10.1016/j.parkreldis.2011.08.010⟩. ⟨hal-01133884⟩

147. Gilles Edan, G. Comi, Emmanuelle Le Page, Emmanuelle Leray, M. Rocca, et al.. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82 (12), pp.1344-1350. ⟨10.1136/jnnp.2010.229724⟩. ⟨hal-02437119⟩

148. Gilles Edan, Emmanuelle Leray. A new treatment era in multiple sclerosis: Clinical applications of new concepts. Journal of the Neurological Sciences, 2011, 306 (1-2), pp.170-172. ⟨10.1016/j.jns.2010.09.018⟩. ⟨hal-02437067⟩

149. Anne Kerbrat, Emmanuelle Le Page, Emmanuelle Leray, T. Anani, M. Coustans, et al.. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. Journal of the Neurological Sciences, 2011, 308 (1-2), pp.98–102. ⟨10.1016/j.jns.2011.05.043⟩. ⟨hal-01147033⟩

150. Emmanuelle Le Page, Emmanuelle Leray, Gilles Edan. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: A 5-year prospective study. Multiple Sclerosis Journal, 2011, 17 (7), pp.867-875. ⟨10.1177/1352458511398371⟩. ⟨hal-02437110⟩

151. Emmanuelle Leray, A Camara, D Drapier, F Riou, N Bougeant, et al.. Prevalence, characteristics and comorbidities of anxiety disorders in France: results from the « Mental Health in General Population » survey (MHGP).. European Psychiatry, 2011, 26 (6), pp.339-45. ⟨10.1016/j.eurpsy.2009.12.001⟩. ⟨hal-01133893⟩

152. Julie Péron, Sarah El Tamer, Didier Grandjean, Emmanuelle Leray, David Travers, et al.. Major depressive disorder skews the recognition of emotional prosody.. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35 (4), pp.987-96. ⟨10.1016/j.pnpbp.2011.01.019⟩. ⟨hal-01133898⟩

2010
153. Sylvie Buffet-Bataillon, Emmanuelle Leray, Magali Poisson, Christian Michelet, Martine Bonnaure-Mallet, et al.. Influence of job seniority, hand hygiene education, and patient-to-nurse ratio on hand disinfection compliance.. Journal of Hospital Infection, 2010, 76 (1), pp.32-5. ⟨10.1016/j.jhin.2010.02.024⟩. ⟨hal-00750826⟩

154. Florence Le Jeune, Marc Vérin, Karim N’Diaye, Dominique Drapier, Emmanuelle Leray, et al.. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study.. Biological Psychiatry, 2010, 68 (11), pp.1016-22. ⟨10.1016/j.biopsych.2010.06.033⟩. ⟨inserm-00667511⟩

155. Julie Péron, Isabelle Biseul, Emmanuelle Leray, Siobhan Vicente, Florence Le Jeune, et al.. Subthalamic nucleus stimulation affects fear and sadness recognition in Parkinson’s disease.. Neuropsychology, 2010, 24 (1), pp.1-8. ⟨10.1037/a0017433⟩. ⟨hal-01133918⟩

2009
156. Philippe Boisrenoult, Sebastien Lustig, Paul Bonnevialle, Emmanuelle Leray, Gilbert Versier, et al.. Vascular lesions associated with bicruciate and knee dislocation ligamentous injury. Orthopaedics & Traumatology: Surgery & Research, 2009, 95 (8), pp. 621-626. ⟨10.1016/j.rcot.2009.10.001⟩. ⟨hal-00981683⟩

157. Sebastien Lustig, Emmanuelle Leray, P Boisrenoult, C Trojani, P Laffargue, et al.. Dislocation and bicruciate lesions of the knee: Epidemiology and acute stage assessment in a prospective series. Orthopaedics & Traumatology: Surgery & Research, 2009, 95, pp. 614-620. ⟨10.1016/j.otsr.2009.10.005⟩. ⟨hal-00980675⟩

158. Julie Péron, Siobhan Vicente, Emmanuelle Leray, Sophie Drapier, Dominique Drapier, et al.. Are dopaminergic pathways involved in theory of mind? A study in Parkinson’s disease. Neuropsychologia, 2009, 47 (2), pp.406-414. ⟨10.1016/j.neuropsychologia.2008.09.008⟩. ⟨hal-02956631⟩

2007
159. Erwan Donal, Noëlle Vignat, Christian de Place, Emmanuelle Leray, Christophe Crocq, et al.. Acute effects of biventricular pacing on right ventricular function assessed by tissue Doppler imaging.. EP-Europace, 2007, 9 (2), pp.108-12. ⟨10.1093/europace/eul175⟩. ⟨inserm-00130056⟩

160. E. Leray, Sp Morrissey, J. Yaouanq, M. Coustans, Emmanuelle Le Page, et al.. Long-term survival of patients with multiple sclerosis in West France. Multiple Sclerosis Journal, 2007, 13 (7), pp.865-874. ⟨10.1177/1352458507077410⟩. ⟨hal-02546138⟩

2006
161. A. Cornillet, Christophe Camus, S. Nimubona, Virginie Gandemer, Pierre Tattevin, et al.. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.. Clinical Infectious Diseases, 2006, 43 (5), pp.577-84. ⟨10.1086/505870⟩. ⟨hal-00699980⟩

1999
162. Aymeric Potteau, Emmanuelle Leray. L’intégration du droit international coutumier dans l’ordre juridique communautaire. La Semaine juridique. Édition générale, 1999, pp.278-281. ⟨hal-02062094⟩

1998
163. Aymeric Potteau, Emmanuelle Leray. Réflexions sur la cohérence du système de contrôle de la légalité des accords internationaux conclus par la Communauté européenne. RTDEur. Revue trimestrielle de droit européen, 1998, 1998 (4), pp.535-571. ⟨hal-02062057⟩

2023
194. Gabrielle De Livron, Marguerite De Livron, Emmanuelle Leray, Cécile Hernandez. La princesse qui se prenait les pieds dans tous les tapis. Presses de l’EHESP, 32p., 2023, 978-2-8109-1092-2. ⟨hal-04020225⟩

2021
195. Mélanie Bertin (Dir.). Glossaire d’épidémiologie. 50 notions pour comprendre la pandémie de Covid-19. Presses de l’EHESP, 48p., 2021, 9782810909537. ⟨10.3917/ehesp.berti.2021.01⟩. ⟨hal-03312283⟩

• Communication

2024
164. D. Logeart, A. Cohen, O. Hanon, P. Jourdain, G. de Pouvourville, et al.. Real-world evaluation of mortality in patients with heart failure treated with Sacubitril-Valsartan in France. JESFC 2024, Jan 2024, Paris, France. pp.S45-S45, ⟨10.1016/j.acvd.2023.10.080⟩. ⟨hal-04414780⟩

165. S. Wilson, Emmanuelle Leray, L. Guittet, G. Defer, O. Dejardin. 12-2 – Inégalités socio-territoriales et mortalité en excès de patients atteints d’une sclérose en plaques en France : une étude rétrospective-observationnelle. Xème Congrès International Francophone Épidémiologie et Santé publique « Les nouvelles transitions épidémiologiques », Association des Épidémiologistes de Langue Française (Adelf); Association pour le développement de l’EPIdémiologie de TERrain (Epiter), Jul 2024, Limoges, France. pp.202611, ⟨10.1016/j.jeph.2024.202611⟩. ⟨hal-04782016⟩

2023
166. Emmanuelle Leray, Xavier Moisset, Chenaf Chouki, Frederic Taithe, Sandra Vukusic, et al.. Risk of relapse after COVID-19 vaccine among patients with multiple sclerosis in France: a self-controlled case series. 9th Joint ECTRIMS-ACTRIMS meeting, Oct 2023, Milan, Italy. ⟨hal-04387686⟩

167. Elisabeth Maillart, Bertrand Bourre, Romain Casey, Kumaran Deiva, Anne-Marie Guennoc, et al.. Pregnancy and birth outcomes in MS women : comparison of the RESPONSE cohort to the general French population. 9th Joint ECTRIMS-ACTRIMS meeting, Oct 2023, Milan, Italy. ⟨hal-04388000⟩

168. Marie Mainguy, Romain Casey, Sandra Vukusic, Emmanuelle Leray, David‐axel Laplaud. Assessing the risk of relapse after in vitro fertilization in women with multiple sclerosis. 9th Joint ECTRIMS-ACTRIMS meeting, Oct 2023, Milan, Italy. ⟨hal-04415216⟩

169. Chloe Pierret, Aurélien Mulliez, Christine Le Bihan-Benjamin, Xavier Moisset, Philippe-Jean Bousquet, et al.. Cancer risk among patients with MS : a 10-year nationwide cohort study using the French medico-administrative database (2012-2021). 9th Joint ECTRIMS-ACTRIMS meeting, Oct 2023, Milan, Italy. ⟨hal-04388002⟩

2021
170. C. Sabathe, Romain Casey, S. Vukusic, Emmanuelle Leray, G. Mathey, et al.. Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct 2021, Virtuel – Online, France. pp.22-24, Oral Presentation 035, ⟨10.1177/13524585211044647⟩. ⟨hal-03464227⟩

• Posters :

2023
Arthur Masson, Benoit Combès, Romain Casey, François Cotton, Alice Dufey, et al.. Can we accurately assess disease activity using automated methods in large real-life MRI databases? Insights from the OFSEP HD database.. 9th Joint ECTRIMS-ACTRIMS meeting, Oct 2023, Milan, Italy. Sage Publications Ltd, Multiple Sclerosis Journal, 29 (3S), pp.P269, 2023. ⟨hal-04732264⟩

2021
197. Izanne Roos, Charles Malpas, Emmanuelle Leray, Romain Casey, Dana Horakova, et al.. Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), Oct 2021, Virtuel – Online, France. Sage, MULTIPLE SCLEROSIS JOURNAL, 27 (Suppl 2), pp.673-676, ePoster 878, 2021. ⟨hal-04772073⟩

2025
198. Bruno Brochet, Laure Carcaillon-Bentata, Abdelilah Abouelfath, Severine Lignot-Maleyran, Patrick Blin, et al.. Validation clinique d’un algorithme d’identification de poussées de sclérose en plaques dans le système national de données de santé (SNDS) [P254]. Journées de Neurologie de Langue Française 2025, Apr 2025, Clermont-Ferrand, France. , Rev Neurol (Paris) – Revue Neurologique (ISSN : 0035-3787), 181 (Suppl.), pp.S35, 2025, ⟨10.1016/j.neurol.2025.01.261⟩. ⟨hal-04999201⟩

199. Jérôme de Sèze, Caroline Papeix, David-Axel Laplaud, Emmanuelle Leray, Mickaël Piotaix, et al.. Données de vie réelle relatives à l’utilisation d’Éculizumab dans la prise en charge des maladies du spectre de la neuromyélite optique (NMOSD) en France : modalités d’utilisation, efficacité et tolérance (ECUP4) [P062]. Journées de Neurologie de Langue Française 2025, Apr 2025, Clermont-Ferrand, France. , Rev Neurol (Paris) – Revue Neurologique (ISSN : 0035-3787), 181 (Suppl.), pp.S134-S135, 2025, ⟨10.1016/j.neurol.2025.01.069⟩. ⟨hal-04999262⟩

2023
200. Arthur Masson, Benoit Combès, Romain Casey, François Cotton, Alice Dufey, et al.. Can we accurately assess disease activity using automated methods in large real-life MRI databases?. MSMilan2023, Oct 2023, Milano (Italy), Italy. 2023. ⟨hal-04250265⟩

• Résumé de conférences

2024
171. Antoine Gavoille, Emmanuelle Leray, Fabien Rollot, Romain Casey, Guillaume Mathey, et al.. Is there therapeutic inertia in women with MS?. 40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Sep 2024, Copenhagen, Denmark. ⟨hal-04888270⟩

172. O. Hanon, A. Cohen, P. Jourdain, E. Leray, G de Pouvourville, et al.. Age-based comparison of patients with heart failure treated with sacubitril-valsartan in France: a real-world evaluation. ESC Congress, Aug 2024, London, United Kingdom. ⟨10.1093/eurheartj/ehae666.926⟩. ⟨hal-04849248⟩

173. Emmanuelle Leray. Enjeux, développements et perspectives de la prise en charge de la SEP. Congrès « Pharmaco-épidémiologie & aide à la décision publique » organisé par EPI-PHARE le 29 novembre 2024, EPI-PHARE, Nov 2024, En ligne, France. ⟨hal-05000510⟩

174. Marie Mainguy, Cécile Donze, Emmanuelle Leray. Rehabilitation care for locomotor disorders in multiple sclerosis. 40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Sep 2024, Copenhagen, Denmark. ⟨hal-04882250⟩

175. A. Mulliez, X. Moisset, C. Chenaf, F. Taithe, S. Vukusic, et al.. P26 – Risque de poussée après vaccination contre le COVID-19 chez les patients atteints de sclérose en plaques en France utilisant un design « self-controlled case series ». EPICLIN 2024, 18ème Conférence francophone d’Épidémiologie Clinique, 31èmes journées des statisticiens des centres de lutte contre le cancer, Réseau national de recherche en épidémiologie clinique et en santé publique (RECaP); Association des Epidémiologistes De Langue Française (ADELF); Réseau national des statisticiens des CLCC, May 2024, Dijon, France. pp.202466, ⟨10.1016/j.jeph.2024.202466⟩. ⟨hal-04578329⟩

176. Chloe Pierret, Sandra Vukusic, Christine Lebrun-Frénay, Géraldine Androdias, Huah Shin Ng, et al.. Multiple sclerosis-related healthcare and disease-modifying drug use before and after a cancer diagnosis. 40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Sep 2024, Copenhagen, Denmark. ⟨hal-04882262⟩

177. C. Pierret, Aurélien Mulliez, Christine Le Bihan-Benjamin, Adil Maarouf, Philippe-Jean Bousquet, et al.. Le risque du cancer dans la SEP : une étude de cohorte nationale (2012–2021). Journées Neurologies de Langue Française 2024, Association JNLF, Apr 2024, Paris, France. pp.S39-S40, ⟨10.1016/j.neurol.2024.02.074⟩. ⟨hal-04529585⟩

178. Chloe Pierret, A. Mulliez, C. Le Bihan-Benjamin, X. Moisset, P-J. Bousquet, et al.. Le risque de cancer dans la sclérose en plaques : une étude de cohorte nationale à partir du Système national des données de santé (SNDS), 2012-2021. Congrès ÉMOIS 2024, Association COPSICOM, Apr 2024, Lille, France. pp.202235, ⟨10.1016/j.jeph.2024.202235⟩. ⟨hal-04543814⟩

179. C. Pierret, L Philippe, Emmanuelle Leray. Dépistage du cancer du sein chez les personnes atteintes de la sclérose en plaques. Congrès ÉMOIS 2024, Apr 2024, Lille, France. pp.202364, ⟨10.1016/j.jeph.2024.202364⟩. ⟨hal-04694861⟩

180. C. Pierret, Lou Philipe, Emmanuelle Leray. Dépistage du cancer du sein chez les personnes atteintes d’une SEP. Journées Neurologies de Langue Française 2024, Apr 2024, Paris, France. pp.S149, ⟨10.1016/j.neurol.2024.02.293⟩. ⟨hal-04529513⟩

181. Sarah Wilson, Emmanuelle Leray, Floriane Calocer, Lydia Guittet, Olivier Dejardin, et al.. Influence des inégalités socio-territoriales sur la mortalité en excès de patients atteints de SEP en France : une étude rétrospective observationnelle. Journées Neurologies de Langue Française 2024, Association JNLF, Apr 2024, Paris, France. pp.S134-S135, ⟨10.1016/j.neurol.2024.02.265⟩. ⟨hal-04530561⟩

2022
182. S. Vukusic, R. Marignier, J. Ciron, B Bourre, M. Cohen, et al.. Pregnancy in women with neuromyelitis optica spectrum disorders: recommendations from the French multiple sclerosis society. 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, European Comm Treatment & Res Multiple Sclerosis, Oct 2022, Amsterdam, Netherlands. pp.40-42 – ref O052. ⟨hal-04989671⟩

2021
183. Pierre Brasseur, Espagnacq Maude, Pichetti Sylvain, Alice Guilleux, Regeart Camille, et al.. Pour l’instant, ça va ! : la déprise professionnelle des personnes avec une sclérose en plaques. Colloque ALTER European Society for Disability Research, Apr 2021, Rennes, France. ⟨halshs-03750919⟩

184. Olivier Grimaud, Anne Girault, Laetitia Laude, Nicolas Sirven, P. Cucharero Atienza, et al.. TRANSCOV, a multidisciplinary project to evaluate long distance COVID patients transfers. 14th European Public Health Conference Public health futures in a changing world, EPH Conference Foundation, Nov 2021, Virtual Event, France. pp.316-316, ⟨10.1093/eurpub/ckab164.837⟩. ⟨hal-03553982⟩

2020
185. Pierre Brasseur, Maude Espagnacq, Sylvain Pichetti, Camille Regaert, Alice Guilleux, et al.. L’invalidité pour les salariés qui ont une sclérose en plaques. Journées des économistes de la santé, Bruxelles, Dec 2020, Bruxelles, Belgique. ⟨halshs-03750922⟩

186. Mathilde Lefort, S. Shannin, Jørgen Vitting Andersen, S. Vukusic, N. J. Koch-Henriksen, et al.. Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology. 6th Congress of the European Academy of Neurology, European Academy of Neurology, May 2020, On line, United Kingdom. pp.342-342. ⟨hal-02887182⟩

187. Hélène Tillaut, A.S. Kerbrat, A. Degremont, Elisabeth Polard, Emmanuelle Leray. Pregnancy outcomes in a French cohort of patients with Multiple Sclerosis: the MUSTANG project. 6th Congress of the European Academy of Neurology, Virtual 2020, European Academy of Neurology, May 2020, ONLINE (Virtual), France. pp.476-476. ⟨hal-02887183⟩

2016
188. Frédéric Balusson, Marie-Anne Botrel, Olivier Dameron, Yann Dauxais, Erwan Drezen, et al.. PEPS: a platform for supporting studies in pharmaco-epidemiology using medico-administrative databases. International Congress on e-Health Research, Oct 2016, Paris, France. ⟨hal-01380939⟩

2015
189. Emmanuelle Leray, J. Roux, Nolwenn Le Meur. Use of administrative database to describe physician services utilization and care patterns in multiple sclerosis in France. Abstracts from the World Congress of Neurology (WCN 2015), Oct 2015, Santiago, Chile. pp.e310–e311, ⟨10.1016/j.jns.2015.08.1092⟩. ⟨hal-01228174⟩

190. Emmanuelle Leray, E. Le Pabic, Christophe Fermanian, J.-C. Ongagna, Denis Bard, et al.. Does air pollution influence risk of relapse in multiple sclerosis?. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct 2015, Barcelona (ES), Spain. ⟨hal-04539462⟩

2013
191. E. Lee, Christophe Fermanian, O. Pez, Emmanuelle Leray, E. Yoon, et al.. Mental Health Disparities between Roma and Non-Roma Children in Romania. XIV. Congress of the International Federation of Psychiatric Epidemiology (IFPE). « The uses of psychiatric epidemiology in improving population mental health », International Federation of Psychiatric Epidemiology (IFPE), Jun 2013, Leipzig (DE), Germany. ⟨hal-04539659⟩

2012
192. N. Durivage, Emmanuelle Leray, Christophe Fermanian, V. Kovess. Parental Use of Corporal Punishment in Europe: Intersection between Public Health and Policy.. 20ème Congrès Mondial de la IACAPAP « Brain, Mind and Development », Association internationale de psychiatrie de l’enfant et de l’adolescent et des professions alliées (IACAPAP), Jul 2012, Paris, France. ⟨hal-04540211⟩

2006
193. A. Cornillet, Christophe Camus, S. Nimubona, Virginie Gandemer, Pierre Tattevin, et al.. Comparison of Clinical and Biological Features of Invasive Aspergillosis in Neutropenic and Non-Neutropenic Patients. 16th Congress of the International Society for Human and Animal Mycology, 2006, Paris, France. ⟨hal-00700372⟩